NASDAQ:GRFS - GRIFOLS S A/S Stock Price, Forecast & News

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

GRIFOLS S A/S declared a semi-annual dividend on Thursday, October 31st. Stockholders of record on Tuesday, December 3rd will be given a dividend of $0.169 per share on Wednesday, December 11th. This represents a dividend yield of 1.3%. The ex-dividend date is Monday, December 2nd. This is a boost from GRIFOLS S A/S's previous semi-annual dividend of $0.15. View GRIFOLS S A/S's Dividend History.

Shares of GRIFOLS S A/S split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly issued shares were distributed to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

GRIFOLS S A/S is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for GRIFOLS S A/S.

5 brokerages have issued 12 month price targets for GRIFOLS S A/S's stock. Their forecasts range from $22.50 to $22.50. On average, they anticipate GRIFOLS S A/S's stock price to reach $22.50 in the next year. This suggests that the stock has a possible downside of 7.8%. View Analyst Price Targets for GRIFOLS S A/S.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GRIFOLS S A/S.

News headlines about GRFS stock have been trending extremely negative on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. GRIFOLS S A/S earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for GRIFOLS S A/S.

GRIFOLS S A/S saw a decline in short interest in February. As of February 14th, there was short interest totalling 1,600,000 shares, a decline of 37.3% from the January 30th total of 2,550,000 shares. Based on an average daily trading volume, of 1,010,000 shares, the short-interest ratio is presently 1.6 days. Currently, 0.6% of the company's shares are short sold. View GRIFOLS S A/S's Current Options Chain.

Some companies that are related to GRIFOLS S A/S include Zoetis (ZTS), Allergan (AGN), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TAK), Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Teva Pharmaceutical Industries (TEVA) and Alnylam Pharmaceuticals (ALNY).

Based on aggregate information from My MarketBeat watchlists, some companies that other GRIFOLS S A/S investors own include Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), Allergan (AGN), Nektar Therapeutics (NKTR), Horizon Therapeutics (HZNP), La Jolla Pharmaceutical (LJPC), Neurocrine Biosciences (NBIX), Supernus Pharmaceuticals (SUPN), AbbVie (ABBV) and Abbott Laboratories (ABT).

GRIFOLS S A/S's stock is owned by many different of retail and institutional investors. Top institutional investors include FIL Ltd (1.78%), Credit Suisse AG (1.76%), Pictet Asset Management Ltd. (1.50%), Capital Research Global Investors (0.63%), Black Creek Investment Management Inc. (0.60%) and UBS Asset Management Americas Inc. (0.44%).

GRFS stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Point72 Asset Management L.P., First Trust Advisors LP, Envestnet Asset Management Inc., Renaissance Technologies LLC, UBS Group AG, CIBC Private Wealth Group LLC and Todd Asset Management LLC.

GRFS stock was acquired by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Amia Capital LLP, Axiom International Investors LLC DE, Janus Henderson Group PLC, UBS Asset Management Americas Inc., FIL Ltd, SG Americas Securities LLC and Marshall Wace LLP.

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GRFS stock can currently be purchased for approximately $24.41.

GRIFOLS S A/S has a market capitalization of $16.78 billion and generates $5.30 billion in revenue each year. The biotechnology company earns $704.63 million in net income (profit) each year or $1.17 on an earnings per share basis. GRIFOLS S A/S employs 21,230 workers across the globe.View Additional Information About GRIFOLS S A/S.

The official website for GRIFOLS S A/S is http://www.grifols.com/.

GRIFOLS S A/S's mailing address is 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 212-969-3335 or via email at [email protected]